Combinations with epidermal growth factor receptor tyrosine kinase inhibitors for treating cancer
JP2025525410A5Pending Publication Date: 2026-07-01ASTRAZENECA AB
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024576475
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-27
- Filing Date
- 2023-06-26
- Publication Date
- 2026-07-01
AI Technical Summary
Technical Problem
There are drug resistance problems in the treatment of NSCLC, especially the resistance caused by T790M mutations, and the existing EGFR and cMET targeted treatments have problems with insufficient safety and effectiveness.
Method used
Develop anti-EGFR/cMET antibody molecules with low affinity EGFR binding domains bind to third-generation TKI to form antibody drug conjugates (ADCs) to improve safety and enhance the therapeutic effect on EGFR-mutant cancers.
Benefits of technology
It improves the therapeutic effect on EGFR-mutant cancer, especially for drug-resistant EGFR-mutant cancers, reduces the toxicity of normal tissues and provides a safe and effective treatment plan.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present disclosure relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anti-EGFR / cMET antibody molecules for use in combination in the treatment of cancer (e.g., non-small cell lung cancer [NSCLC]).
Need to check novelty before this filing date? Find Prior Art